News Detail
London, 30 Sept 2023: Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viru......
View Details
Source : University of Cambridge
Molnupiravir
an antiviral drug
COVID-19
SARS-CoV-2 to mutate
Department of Medicine
Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID)
Cambridge Infectious Diseases
Cambridge Fights COVID
Related News
- Mandimycin: A polyene antifungal with a unique mode of action (22-03-2025)
- Newly identified bacterial protein helps design cancer drug delivery system (21-03-2025)
- IIT Roorkee researchers identify a potential drug against Chikungunya (18-03-2025)
- New test enables doctors to anticipate a serious side effect of cancer therapy (17-03-2025)
- Chinese vaccine shows promise in stopping plaque build-up in arteries (15-03-2025)
- Researchers develop technique for storing life-saving drugs without temperature control (15-03-2025)
- NIT researchers develop eco-friendly process to remove pharmaceutical pollutants from wastewater (14-03-2025)
- New personalised vaccine shows promise in treating deadly pancreatic cancer (13-03-2025)
- Human body's protein recycling system fights bacteria like antibiotics: Study (06-03-2025)
- Researchers at IIT Kanpur Identify Crucial Drug Target Receptor for Treating Cancer and Respiratory Diseases (22-02-2025)